Relapsed or Refractory Classical Hodgkin's Lymphoma (DBCOND0125653)

Identifiers

Synonyms

Relapsed/Refractory Classical Hodgkins Lymphoma / Relapsed/Refractory Classical Hodgkin Lymphoma / Relapsed/Refractory Classical Hodgkin's Lymphoma / Refractory or Relapsed Classical Hodgkin Lymphoma / Relapsed or Refractory Classical Hodgkin Lymphoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05140382	AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL	Zemirciclib	treatment	2	completed
NCT05243693	Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma	Brentuximab vedotin	treatment	2	recruiting
NCT03114683	Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma	No drug interventions	treatment	2	completed
NCT04624984	PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL	Doxorubicin Gemcitabine Vinorelbine	treatment	2	recruiting
NCT04237233	Intense Monitoring Study on Tyvyt	No drug interventions	Not Available	Not Available	unknown_status
NCT03327571	B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes	No drug interventions	Not Available	Not Available	completed
NCT05216835	Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Sabestomig	treatment	1 / 2	active_not_recruiting